Reducing Cardiometabolic Risk with SGLT2i and GLP1-RA

- How to Choose and in Who

Qin Yang MD PhD Endocrinology UC Irvine Health

I have no relevant financial relationships to disclose

Notable updates to the Standards of Care in Diabetes—2023



Emphasis on supporting **higher weight loss (up to 15%)** based on the section the section of the section of and access to newer medications when appropriate

The **expanded role of SGLT2 inhibitor use** in preserved and reduced heart failure ejection fraction

New recommendations related to **sleep health and physical activity** in people with diabetes

Broad consideration of **social determinants of health** in guiding the design and delivery of care


New **hypertension diagnosis cut-offs** (hypertension is now defined as a systolic blood pressure ≥130 mmHg or a diastolic blood pressure ≥80 mmHg)

The **role of finerenone** in individuals with diabetes and chronic kidney disease with albuminuria

New **lipid management recommendations** suggesting lower LDL goals for high-risk individuals

Symposium for Cardiovascular Disease Prevention

Guidelines and societies recommend the use of SGLT2 inhibitors and/or GLP-1 RAs for their metabolic, CV and kidney benefits




ASCVD, atherosclerotic cardiovascular disease; CVD, cardiovascular disease; DKD, diabetic kidney disease; HFmrEF, heart failure with mildly reduced eject fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HFDISEASE Prevention See slide notes for full list of references Goal: Cardiorenal Risk Reduction in High-Risk Patients with Type 2 Diabetes (In addition to comprehensive CV risk management)*

Pharmacologic Therapy for Adults With Type 2 Diabetes

Among individuals with type 2 diabetes who have

established ASCVD
indicators of high CV risk
established kidney disease
heart failure

A sodium-glucose cotransporter 2 (SGLT2) inhibitor and/or glucagon-like peptide 1 (GLP-1) receptor agonist is recommended as part of the glucoselowering regimen and comprehensive CV risk reduction, independent of A1C and in consideration of person-specific factors.



.


.

·


.

If additional cardiorenal risk reduction or glycaemic lowering needed

GLP1 and long-acting GLP1-RA




GLP1-RAs and cardiovascular outcomes



HR (95% CI)


Nauck MA et al., Front in Endo 2021

Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6




Marso SP et al., NEJM 2016 Husain M et al., NEJM 2019


Glycemic control and weight loss in the SUSTAIN 6 and PIONEER 6




Lancet 2021; 397: 971-84 STEP 2 Trial A higher dose of Semaglutide at 2.4mg is more effective for weight loss



Preliminary report: Subcutaneous once-weekly semaglutide 2.4 mg was associated with a statistically significant 20% reduction in major adverse cardiovascular events (MACE) compared with placebo.




Incretins – GLP1 and GIP



Tirzepatide – dual GLP1 and GIP receptor agonist

C20 fatty diacid,

H₂N-Y-NH



JULY 21, 2022 SURMOUNT-1 Trial

cardiovascular

Tirzepatide, active.


Tirzepatide Once Weekly for the Treatment of Obesity


	Tirzepatide,	Tirzepatide, 10 mg	Tirzepatide, 15 mg	Placebo	Total
Characteristic	5 mg (N=630)	(N=636)	(N=630)	(N = 643)	(N=2539)
Age — yr	45.6±12.7	44.7±12.4	44.9±12.3	44.4±12.5	44.9±12.5
Female sex — no. (%)	426 (67.6)	427 (67.1)	425 (67.5)	436 (67.8)	1714 (67.5)
White	447 (71.0)	452 (71.1)	443 (70.3)	450 (70.0)	1792 (70.6)
Body weight — kg	102.9±20.71	105.8±23.32	105.6±22.92	104.8±21.37	104.8±22.12
Mean body-mass index	37.4±6.63	38.2±7.01	38.1±6.69	38.2±6.89	38.0±6.81
Glycated hemoglobin — %	5.6±0.36	5.6±0.37	5.6±0.41	5.6±0.38	5.6±0.38

B Percent Change in Body Weight by Week (efficacy estimand)

The NEW ENGLAND

JOURNAL of MEDICINE






outcomes

trial


for

Weight Management: Metabolic Surgery

C Weight loss



GLP1/GIP/Glucagon Tri-Agonist



TO BE CONTINUED...

Mingrone et al. The Lancet. 2021 23;397:293-304


GLP1-RAs, how to choose and in who

• Theoretically, most of the obese patients

- With clinical ASCVD or high risk – Liraglutide, Semaglutide, or Dulaglutide, Tirzepatide should work too, although perspective trial data available yet.

- If weight loss is the main goal, Tirzepatide and Semaglutide are stronger.
- For obese patients with Type 2 diabetes, early treatment may be important.

Intensive Structured Weight Management: the DiRect RCT



- 10 kg at 2 year followup = 64% diabetes remission

Table 4 Estimated Cardiovascular Events and Preventable Events, based on BMI parameters

From: <u>US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity</u> <u>Prevalence and Cardiovascular Disease Events</u>

	n (M)	CVD Risk Pre-Treatment (%)	CVD Risk Post-Treatment (%)	Difference	CVD Events Pre	CVD Events Post	Difference
Overall	3493 (82.8M)	10.15%	8.34%	1.81%	355 (8.41 M)	291 (6.91 M)	63 (1.50 M)
Females	1915 (42.2M)	7.64%	6.24%	1.41%	146 (3.22 M)	119 (2.63 M)	27 (0.59 M)
Males	1578 (41.5M)	12.71%	10.51%	2.20%	201 (5.27 M)	166 (4.36 M)	35 (0.91 M)
Whites	1187 (50.1M)	11.60%	9.59%	2.01%	138 (5.81 M)	114 (4.80 M)	24 (1.01 M)
Asians	210 (2.1M)	7.07%	5.79%	1.28%	15 (0.15 M)	12 (0.12 M)	3 (0.03 M)
Blacks	833 (9.8M)	9.00%	7.39%	1.61%	75 (0.88 M)	62(0.72M)	13 (0.16 M)
Hispanic	1087 (14.8M)	6.95%	5.68%	1.27%	76 (1.03 M)	62(0.84M)	14 (0.19 M)
Other	176 (4.0M)	6.64%	5.43%	1.21%	12 (0.27 M)	10 (0.22 M)	2 (0.05 M)

Estimates combining strata may not total overall due to rounding error

GLP1-RAs, risk considerations

Box 1. Who should not receive a GLP-1 receptor agonist?

- Type 1 diabetes.
- Pregnancy and breastfeeding.
- Severe gastrointestinal disease (e.g. inflammatory bowel disease).
- Diabetic gastroparesis.
- History of pancreatitis.
- Caution if high risk of pancreatitis (e.g. gallstones, alcohol excess, hypertriglyceridaemia).
- History of medullary thyroid cancer or multiple endocrine neoplasia (MEN) type 2.
- Caution in renal impairment see Table 1.

Make sure to ask your patient who is using a GLP1-RA to stop the treatment one week before procedures.

Table 2. Risks of Biliary Disease, Pancreatitis, Bowel Obstruction, and Gastroparesis Among Users of GLP-1 Agonists vs Bupropion-Naltrexone

	GLP-1 agonists, HR (95%			
Outcomes	Crude	Adjusted ^b	Bupropion-naltrexone	
Primary analysis				
Biliary disease	1.48 (0.88-2.47)	1.50 (0.89-2.53)	1 [Reference]	
Pancreatitis	10.33 (1.44-74.40)	9.09 (1.25-66.00)	1 [Reference]	
Bowel obstruction	5.16 (1.27-21.00)	4.22 (1.02-17.40)	1 [Reference]	
Gastroparesis	3.31 (1.04-10.50)	3.67 (1.15-11.90)	1 [Reference]	
Sensitivity analyses				
Exclusion of hyperlipidemia				
Biliary disease	1.50 (0.88-2.56)	1.46 (0.84-2.51)	1 [Reference]	
Pancreatitis	9.80 (1.36-70.79)	7.99 (1.10-58.30)	1 [Reference]	
Bowel obstruction	4.43 (1.08-18.20)	3.63 (0.87-15.10)	1 [Reference]	
Gastroparesis	3.32 (1.04-10.60)	3.67 (1.14-11.80)	1 [Reference]	
Analysis with less-restrictive obesity definition ^c				
Biliary disease	1.29 (0.92-1.80)	1.20 (0.85-1.69)	1 [Reference]	
Pancreatitis	6.19 (1.99-19.30)	5.94 (1.90-18.60)	1 [Reference]	
Bowel obstruction	3.11 (1.28-7.54)	2.44 (1.00-5.95)	1 [Reference]	
Gastroparesis	2.11 (1.09-4.09)	2.35 (1.20-4.58)	1 [Reference]	
E-values for adjusted HRs ^d				
Biliary disease	2.36			
Pancreatitis	17.67			
Bowel obstruction	7.91	Sodhi M	et al., JAMA 2023	
Gastroparesis	6.80			

Is GLP1-RA treatment linked to thyroid cancer?

Connected for Life


The use of GLP-1 receptor agonists is associated with an increased risk of thyroid cancer

Bezin J., Gouverneur A., Pénichon M., Mathieu C., Garrel R., Hillaire-Buys D., Pariente A., Faillie J-L. GLP-1 receptor ago Nationwide population-based study on French SNDS database Cumulative use ≤1 3,746,672 individuals with type 2 diabetes treated with second-line antidiabetes drugs between 2006-2018 DPP-4 inhibitors	2,255 (8 31 year 117 (4 1-3 years 112 (4	1,767 (3.9)			
Nationwide population-based study on French SNDS database Cumulative use ≤1 Cumulative use ≤1 3,746,672 individuals with type 2 diabetes treated with second-line antidiabetes drugs between 2006-2018 DPP-4 inhibitors	117 (4 -3 years 112 (4	1,767 (3.9)			
Nationwide population-based study on French SNDS databaseCumulative use 1- Cumulative use > Cumulative use > 	-3 years 112 (4		1.22 (0.99 to 1.50		
French SNDS databaseCumulative use 1- Cumulative use 2- Cumulative use 2- Cumulative use 2- DPP-4 inhibitors3,746,672 individuals with type 2 diabetes treated with second-line antidiabetes drugs between 2006-2018DPP-4 inhibitors No use		1.419 (3.1)			
3,746,672 individuals with type 2 diabetes treated with second-line antidiabetes drugs between 2006-2018			1.58 (1.27 to 1.95		
treated with second-line antidiabetes drugs between 2006-2018 No use	•3 years 78 (3.	.0) 1,162 (2.6)	1.36 (1.05 to 1.74		
between 2006-2018 No use					
Cumulative use <1	1,522 (5	59.4) 27,406 (60.7) Reference		
	1 year 333 (13	3.0) 5,209 (11.5)	1.12 (0.99 to 1.28		
2,562 cases of thyroid cancers Cumulative use 1-	-3 years 310 (12	2.1) 5,918 (13.1)	0.96 (0.84 to 1.10		
45,184 matched control subjects	3 years 397 (15	5.5) 6,651 (14.7)	1.19 (1.04 to 1.35		
*Adjusted for social deprivati	*Adjusted for social deprivation index, goiter, hypo- and hyperthyroidism in the last year, and use of other antidiabetes drugs in the last 6 years considered in therapeutic class.				

• The paper is widely published on social media, but the association between GLP1-RA treatment and thyroid cancer is unclear.

necessarily represent the opinion of the French Medicines Agency


 Secondary analysis using the same data set found that other diabetes and hypertension medications are also associated with thyroid cancer.



A subsequent study found that GLP1-RA treatment did not increase thyroid risk compared with insulin treatment.

SGLT2 inhibition reduces reabsorption of glucose into the bloodstream resulting in glucose passing through the urine.

Schematic View of the Kidney in People with Poorly Controlled T2D



SGLT2 inhibitors

Urinary glucose excretion, loss of calories from the body

Mechanism of action	 Inhibits SGLT2 (sodium/glucose cotransporter 2) in the proximal tubule, blocking reabsorption of filtered glucose (leading to osmotic diuresis)
Examples (_ gliflozin)	 Empagliflozin (Jardiance[®]) - Best risk/benefit ratio of the three Dapagliflozin (Forxiga[®]) Canagliflozin (Invokana[®])
Major advantages	 Weight loss (~2-3kg) Empagliflozin and canagliflozin ↓ CV mortality in high risk patients with T2D + atherosclerotic heart disease All 3 ↓ heart failure hospitalizations and progression of nephropathy

JAMA Cardiology | Original Investigation


Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes A Meta-analysis

0.2

0.2


A Overall MACEs

	Treatment		Placebo			
	No./total No.	Rate/1000 patient-years	No./total No.	Rate/1000 patient-years	Hazard ratio (95% CI)	
EMPA-REG OUTCOME	490/4687	37.4	282/2333	43.9	0.86 (0.74-0.99)	
CANVAS program	NA/5795	26.9	NA/4347	31.5	0.86 (0.75-0.97)	
DECLARE-TIMI 58	756/8582	22.6	803/8578	24.2	0.93 (0.84-1.03)	
CREDENCE	217/2202	38.7	269/2199	48.7	0.80 (0.67-0.95)	
VERTIS CV	735/5499	40.0	368/2747	40.3	0.99 (0.88-1.12)	
Fixed-effects model (Q=	5.22; df = 4; P = .2	27; 1 ² = 23.4%)			0.90 (0.85-0.95)	



B MACEs by ASCVD status

	Treatment		Placebo		
	No./total No.	Rate/1000 patient-years	No./total No.	Rate/1000 patient-years	Hazard ratio (95% CI)
Patients with ASCVD					
EMPA-REG OUTCOME	490/4687	37.4	282/2333	43.9	0.86 (0.74-0.99)
CANVAS program	NA/3756	34.1	NA/2900	41.3	0.82 (0.72-0.95)
DECLARE-TIMI 58	483/3474	36.8	537/3500	41.0	0.90 (0.79-1.02)
CREDENCE	155/1113	55.6	178/1107	65.0	0.85 (0.69-1.06)
VERTIS CV	735/5499	40.0	368/2747	40.3	0.99 (0.88-1.12)
Fixed-effects model (Q=	= 4.53; df = 4; P =	=.34; I ² = 11.8%)			0.89 (0.84-0.95)
Patients without ASCVD					
CANVAS program	NA/2039	15.8	NA/1447	15.5	0.98 (0.74-1.30)
DECLARE-TIMI 58	273/5108	13.4	266/5078	13.3	1.01 (0.86-1.20)
CREDENCE	62/1089	22.0	91/1092	32.7	0.68 (0.49-0.94)
Fixed-effects model (Q=	= 4.59; df = 2; P =	=.10; I ² = 56.5%)			0.94 (0.83-1.07)




Similar results were observed in CV death (event reduction in patients with ASCVD, not in patients without ASCVD)

But HF is improved in patients with or without ASCVD

A Overall HHF

	Treatment		Placebo		
	No./total No.	Rate/1000 patient-years	No./total No.	Rate/1000 patient-years	Hazard ratio (95% CI)
EMPA-REG OUTCOME	126/4687	9.4	95/2333	14.5	0.65 (0.50-0.85)
CANVAS program	NA/5795	5.5	NA/4347	8.7	0.67 (0.52-0.87)
DECLARE-TIMI 58	212/8582	6.2	286/8578	8.5	0.73 (0.61-0.88)
CREDENCE	89/2202	15.7	141/2199	25.3	0.61 (0.47-0.80)
VERTIS CV	139/5499	7.3	99/2747	10.5	0.70 (0.54-0.90)
Fixed-effects model (Q=	0.68 (0.61-0.76)				



HR (95% CI)

19.62 17.13 29.66 12.74 20.84


16.38 55.07 28.56

0.2

B HHF by ASCVD status


	Treatment		Placebo			
	No./total No.	Rate/1000 patient-years	No./total No.	Rate/1000 patient-years	Hazard ratio (95% CI)	Favors Favors treatment placebo
Patients with ASCVD						
EMPA-REG OUTCOME	126/4687	9.4	95/2333	14.5	0.65 (0.50-0.85)	├─●──┤
CANVAS program	NA/3756	7.3	NA/2900	11.3	0.68 (0.51-0.90)	├──● ──┤
DECLARE-TIMI 58	151/3474	11.1	192/3500	14.1	0.78 (0.63-0.97)	
CREDENCE	59/1113	20.6	92/1107	33.2	0.61 (0.44-0.85)	
VERTIS CV	139/5499	7.3	99/2747	10.5	0.70 (0.54-0.90)	
Fixed-effects model (Q	= 1.97; df = 4; P =	=.74; <i>I</i> ² =0.0%)			0.70 (0.62-0.78)	\diamond
Patients without ASCVD						
CANVAS program	NA/2039	2.6	NA/1447	4.2	0.64 (0.35-1.15)	
DECLARE-TIMI 58	61/5108	3.0	94/5078	4.6	0.64 (0.46-0.88)	
CREDENCE	30/1089	10.6	49/1092	17.5	0.61 (0.39-0.96)	
Fixed-effects model (Q	=0.03; df = 2; P =	=.99; I ² =0.0%)			0.63 (0.50-0.80)	
					C).2 1

Effects of SGLT2 inhibitors on hospitalization for heart failure




A Overall kidney outcomes

	Treatment		Placebo			
	No./total No.	Rate/1000 patient-years	No./total No.	Rate/1000 patient-years	Hazard ratio (95% CI)	
EMPA-REG OUTCOME	81/4645	6.3	71/2323	11.5	0.54 (0.40-0.75)	
CANVAS program	NA/5795	5.5	NA/4347	9.0	0.60 (0.47-0.77)	
DECLARE-TIMI 58	127/8582	3.7	238/8578	7.0	0.53 (0.43-0.66)	
CREDENCE	153/2202	27.0	224/2199	40.4	0.66 (0.53-0.81)	
VERTIS CV	175/5499	9.3	108/2747	11.5	0.81 (0.64-1.03)	
Fixed-effects model (Q=7	.96; df = 4; P = .0)9; / ² = 49.7%)			0.62 (0.56-0.70)	



B Kidney outcomes by ASCVD status

	Treatment		Placebo		
	No./total No.	Rate/1000 patient-years	No./total No.	Rate/1000 patient-years	Hazard ratio (95% CI)
Patients with ASCVD					
EMPA-REG OUTCOME	81/4645	6.3	71/2323	11.5	0.54 (0.40-0.75)
CANVAS program	NA/3756	6.4	NA/2900	10.5	0.59 (0.44-0.79)
DECLARE-TIMI 58	65/3474	4.7	118/3500	8.6	0.55 (0.41-0.75)
CREDENCE	69/1113	24.1	102/1107	36.5	0.64 (0.47-0.87)
VERTIS CV	175/5499	9.3	108/2747	11.5	0.81 (0.64-1.03)
Fixed-effects model (Q	=6.09; df = 4; P	= .19; <i>I</i> ² = 34.4%)			0.64 (0.56-0.72)
Patients without ASCVD					
CANVAS program	NA/2039	4.1	NA/1447	6.6	0.63 (0.39-1.02)
DECLARE-TIMI 58	62/5108	3.0	120/5078	5.9	0.51 (0.37-0.69)
CREDENCE	84/1089	29.9	122/1092	44.3	0.68 (0.51-0.89)
Fixed-effects model (Q	= 1.86; df = 2; P	=.40; <i>I</i> ² =0.0%)			0.60 (0.50-0.73)
		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			



Effects of SGLT2 inhibitors on kidney-related outcomes

0.2

Effect of SGLT2 inhibitors in HHF or CV death, HHF alone and CV death alone

	EMPA-REG OUTCOME ¹ (empagliflozin)	CANVAS Program ^{2,3} (canagliflozin)	DECLARE-TIMI 58 ⁴ (dapagliflozin)	CREDENCE ⁵ (canagliflozin)	VERTIS CV ⁶ (ertugliflozin)
HHF or CV death	34% p<0.001	22% <i>p</i> -value not reported	17% p=0.005	31% p<0.001	12% p=0.11
HHF	35% <i>p</i> =0.002	33% <i>p</i> -value not reported	27% <i>p</i> -value not reported	39% <i>p</i> <0.001	30% <i>p</i> -value not reported
CV death	38% p<0.001	13% <i>p</i> -value not reported	2% <i>p</i> -value not reported	22% p=0.05	8% <i>p</i> -value not reported

15th Annual Orange County

Comparison of studies should be interpreted with caution due to differences in study design, populations an Symposium for Cardiovascular HHF, hospitalisation for heart failure

1. Zinman B et al. N Engl J Med 2015;373:2117; 2. Neal B et al. N Engl J Med 2017;377:644; 3. Rådholm K et al. Circu Disease, Prevention

4. Wiviott S et al. N Engl J Med 2019;380:347; 5. Perkovic V et al. N Engl J Med 2019;380:2295; 6. Cannon C et al. N Engl J Med 2020;383:1425

SGLT2 inhibitors, contraindications and side effects

Contraindications and precautions

- Type 1 diabetes
- Type 2 diabetes and eGFR <45 mL/min/1.73 m2 (ertugliflozin), or <30 mL/min/1.73 m2 (empagliflozin, canagliflozin, dapagliflozin, bexagliflozin)
- Prior diabetic ketoacidosis (DKA)

Side effects.


- Genitourinary tract bacterial and yeast infections.
- Bone loss and fracture. SGLT2 inhibitors have been associated with fracture risk in some (Canagliflozin), but not all, studies.
- Mild volume loss.
- Lower extremity infection and amputation. SGLT2 inhibitors are associated with a small risk of lower extremity infection and amputation.
- DKA.
- 15th Annual Orange County Symposium for Cardiovascular Disease Prevention

SGLT2 inhibitor and genital infection


EMPA-REG OUTCOME Safety Results

Event		Pooled Empagliflozin (%)	Placebo (%)
Any adverse event		90.2	91.7
Serious adverse event		38.2	42.3
Death		3.8	5.1
Any hypoglycemia		27.8	27.9
Severe hypoglycemia		1.3	1.5
Urinary tract infection	Male	10.5	9.4
	Female	36.4	40.6
Genital infection	Male	5.0	1.5
	Female	10.0	2.6
Volume depletion		5.1	4.9
Diabetic ketoacidosis		0.1	<0.1
Bone fracture		3.8	3.9

CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; MI, myocardial infarction. Zinman B, et al. N Engl J Med. 2015;373:2117-2128.



McGovern AP et al., BMJ Open Diabetes 2020



Hamblin PS et al., JCEM 2019




Figure adapted from ADA-EASD consensus report. Davies MJ et al. Diabetes Care 2022;45:2753. There are additional recommendations If HbA1c remains above target; for full recommendations, please refer to the reference.


1. American Diabetes Association. Diabetes Care 2023;46:S1; 2. Davies MJ et al. Diabetes Care 2022;45:2753

Please see speaker notes for footnotes and abbreviations

Patient question: Can I stop GLP1-RA treatment after weight loss?

JAMA | Original Investigation JAMA. 2021;

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial



STEP 4 Trial

D Proportion of participants achieving thresholds of weight loss during the entire trial (weeks 0-68; observed in-trial data)

